Are Chinese Medicine Purchasing Agents Reliable? A Systematic Analysis from Regulation, Supply Chain, and Accountability

By:DengYue International Business Division

In recent years, with the rapid advancement of China’s innovative drug development, an increasing number of targeted therapies, immunotherapies, and antibody-drug conjugates (ADCs) have been approved for market use. As a result, some overseas patients and research institutions—facing delayed local approvals or significant price differences—have turned to “purchasing agents” to obtain medicines from China.

However, from an industry perspective, this model is neither stable nor sustainable. Rather than asking whether it is “reliable,” it is more meaningful to analyze its inherent limitations from three key dimensions by Dengyue: regulatory framework, supply chain structure, and accountability mechanisms.

1. Regulatory Complexity: Why Informal Procurement Models Face Structural Limitations

Unlike general consumer goods, pharmaceuticals are subject to strict regulatory oversight in cross-border circulation. This typically involves:

● Export country regulatory authorities (e.g., China’s National Medical Products Administration, NMPA)

● Transit region regulatory systems (e.g., Hong Kong Department of Health)

● Import country pharmaceutical and customs regulations

Under such a framework, legal pharmaceutical distribution generally requires:

● Complete commercial and medical documentation

● Valid export and import qualifications

● Standardized declaration procedures

The purchasing agent model, by nature, operates outside standardized distribution channels and often fails to meet these compliance requirements. As a result, shipments frequently face uncertainty during customs clearance, including detention, delays, or even destruction.

2.  Cold Chain and Quality Control: Limitations of Informal Logistics Systems

In oncology and advanced therapeutics, many drugs are highly temperature-sensitive, including:

● Targeted therapies

● Monoclonal antibodies

● ADC drugs

● RNA-based therapies

These medicines typically require strict temperature-controlled transportation (e.g., 2–8°C) with continuous monitoring and recorded data to ensure stability and efficacy.

In professional pharmaceutical supply chains, cold chain management includes:

● Standardized packaging solutions

● Temperature-controlled equipment and monitoring systems

● Real-time tracking and exception handling mechanisms

In contrast, purchasing agents often rely on conventional shipping methods without systematic temperature control or data recording. Even when products appear intact, their actual quality and efficacy cannot be reliably verified.

3. Source Authenticity and Traceability: Structural Risks in Non-Standard Channels

One of the core requirements in pharmaceutical distribution is traceability, which includes:

● Clear origin (manufacturer, batch information)

● Transparent distribution pathway

● Identifiable responsible parties

Purchasing agents typically operate through individuals or non-standard intermediaries, resulting in opaque supply chains and incomplete traceability. This creates structural risks such as:

● Unclear product origin

● Potential exposure to unauthorized or non-compliant sources

● Inability to verify storage and transportation history

For high-value, high-risk products such as oncology drugs, these risks are particularly critical.

4. Lack of Accountability: Why the Model Cannot Support Medical-Grade Demand

In compliant pharmaceutical distribution systems, responsibilities are clearly defined, including:

● Supplier accountability

● Logistics responsibility

● Documentation and compliance obligations

When issues arise—such as shipment damage, delays, or quality disputes—there are established mechanisms for resolution.

In contrast, the purchasing agent model is essentially a point-to-point transaction without a formal accountability framework. As a result:

● Service reliability cannot be guaranteed

● Long-term treatment needs cannot be supported

● It is unsuitable for clinical research or institutional procurement

5. From Informal Purchasing to Structured Supply Systems

As cross-border medical demand continues to grow, more professional users are shifting from informal purchasing agents to compliant supply systems. This transition reflects a broader shift:

● From non-standard pathways to regulated channels

● From uncertainty to process control

● From one-time transactions to long-term service models

In this context, qualified pharmaceutical suppliers with established supply chain capabilities are becoming the preferred solution.

6. DengYueMed: A Practical Model for Compliant Cross-Border Pharmaceutical Supply

As a Hong Kong Department of Health-certified pharmaceutical import and export wholesaler, DengYueMed has developed a structured, compliance-oriented supply system for international clients. Its key strengths include:

1. Compliant Export Framework

Leveraging Hong Kong’s role as an international pharmaceutical trade hub, DengYueMed establishes legal and standardized export pathways aligned with regulatory requirements.

2. Standardized Cold Chain Logistics

For temperature-sensitive products such as ADCs and biologics, DengYueMed provides full-process temperature-controlled transportation and monitoring to ensure drug stability.

3. Documentation and Customs Support

Comprehensive documentation preparation and customs clearance assistance reduce uncertainty in cross-border distribution.

4. Traceable Supply Chain

Ensuring legitimate sourcing and transparent distribution pathways, meeting the quality requirements of both clinical and research use.

Through this system, DengYueMed transforms pharmaceutical procurement from an informal, risk-prone activity into a controlled and professional supply solution—suitable for long-term treatment, research projects, and institutional needs.

7. Conclusion

From the perspectives of regulation, supply chain, and accountability, the purchasing agent model lacks the structural foundation required for stable and sustainable pharmaceutical distribution. Its risks are systemic rather than incidental.

For overseas users seeking access to Chinese medicines, a more rational approach is to work with qualified suppliers that offer compliant and structured solutions.

In this regard, DengYueMed provides a safer, more reliable, and scalable model for cross-border pharmaceutical supply through its Hong Kong-based compliance framework, cold chain capabilities, and integrated service system.